A report from Childrens Oncology Group (COG) of a cohort of patients with relapsed/refractory NB treated with irinotecan (I), temozolomide (T), dinutuximab, and GM-CSF showed major objective responses in 22 (41.5%) of 53 patients [16]. This evidence concerns the gene CSF2 and neuroblastoma.